Acorda Therapeutics to Host Conference Call to Discuss Second Quarter Results on July 30, 2015
July 23 2015 - 07:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that it will
host a conference call and webcast to report its second quarter
2015 financial results and pipeline updates on Thursday, July 30 at
8:30 a.m. ET.
To participate in the conference call, please dial 855.542.4209
(domestic) or 412.455.6054 (international) and reference the access
code 83307996. The presentation will be available via a live
webcast on the Investors section of www.acorda.com. Please log in
approximately 5 minutes before the scheduled time of the
presentation to ensure a timely connection.
A replay of the call will be available from 1:30 p.m. ET on July
30, 2015 until 11:59 p.m. on August 6, 2015. To access the replay,
please dial 855.859.2056 (domestic) or 404.537.3406 (international)
and reference the access code 83307996. The archived webcast will
be available in the Investor Relations section of the Acorda
website at www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company
focused on developing therapies that restore function and improve
the lives of people with neurological disorders.
Acorda markets three FDA-approved therapies, including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg. The Company has
one of the leading pipelines in the industry of novel neurological
therapies. Acorda is currently developing a number of clinical and
preclinical stage therapies. This pipeline addresses a range of
disorders including post-stroke walking deficits, Parkinson’s
disease, epilepsy, neuropathic pain, heart failure, MS and spinal
cord injury.
For more information, please visit the Company’s website at:
www.acorda.com.
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or
prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially, including the ability to realize the
benefits anticipated from the Civitas transaction and to
successfully integrate Civitas' operations into our operations; our
ability to successfully market and sell Ampyra in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz, or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully
market CVT-301, Plumiaz, or any other products under development;
we may need to raise additional funds to finance our expanded
operations and may not be able to do so on acceptable terms; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence
on our collaboration partner Biogen in connection therewith;
competition; failure to protect our intellectual property, to
defend against the intellectual property claims of others or to
obtain third party intellectual property licenses needed for the
commercialization of our products; and, failure to comply with
regulatory requirements could result in adverse action by
regulatory agencies.
These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this release are made only as of the date hereof, and Acorda
disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150723005014/en/
Acorda TherapeuticsFelicia Vonella,
914-326-5146fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2023 to Mar 2024